Anteris Technologies Success with DurAVR® Transcatheter Heart Valve
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a pioneering structure heart company dedicated to creating life-enhancing medical devices, recently shared promising one-year results related to their innovative DurAVR® Transcatheter Heart Valve (THV). This was particularly notable among patients suffering from severe symptomatic aortic stenosis with small aortic annuli.
The DurAVR® THV system showcased remarkable performance metrics, including low mean gradients and sizeable effective orifice areas (EOAs), as well as no valve-related mortality reported over the one-year span. These outcomes are significant, particularly for those with smaller aortic annuli, a group that typically faces numerous challenges when undergoing such procedures.
Key Findings from the One-Year Reports
The highlights from the one-year results include:
Impressive Hemodynamic Profile
The DurAVR® THV maintained a favorable hemodynamic profile throughout the one-year study period. With an EOA measuring 2.1 ± 0.2 cm² and a mean pressure gradient (MPG) of 8.6 ± 2.6 mmHg, the numbers indicate a highly efficient flow. Importantly, these values reflect how well the device performs, ensuring optimal blood flow for the patients.
Clinical Safety Outcomes
The safety outcomes of this valve were equally commendable. There were zero instances of valve-related mortality and no occurrences of moderate or severe paravalvular leakage within the year. This data strengthens the potential of the DurAVR® THV as a reliable option for patients and healthcare providers.
Prosthesis-Patient Mismatch
Another vital metric noted is the low prosthesis-patient mismatch (PPM) rate. At just 1.5% after 30 days, this is significantly lower in contrast to the 11.2% to 35.3% rates reported in existing commercial devices. This demonstrates the DurAVR® THV's efficacy in addressing one of the main concerns traditionally associated with transcatheter aortic valve replacements.
The Importance of Optimization for Small Annuli Patients
Dr. Rishi Puri, a prominent cardiologist at the Cleveland Clinic, emphasized the necessity of optimizing physiological flow for patients with small annuli. Even slight inefficiencies in hemodynamics can adversely affect long-term results. Dr. Puri highlighted that the DurAVR® valve has shown its capacity to restore laminar flow and maintain favorable hemodynamics, greatly contributing to the success rates observed in this patient demographic.
The data arose from a combined cohort of 65 patients who received the DurAVR® THV through the ongoing EMBARK study as well as the US Early Feasibility Study (EFS). Given that over 100 patients have now received the DurAVR® THV, the results are encouraging, promising further validation in a forthcoming pivotal trial known as the PARADIGM Trial.
Future Trials and Prospective Impact
The PARADIGM Trial, listed on ClinicalTrials.gov with ID NCT07194265, is set to be a landmark prospective randomized controlled trial that will compare the DurAVR® THV against commercially available transcatheter aortic valve replacements for treating severe aortic stenosis. This trial's outcomes are highly anticipated as they will provide critical insights into the technology's long-term effectiveness and safety.
About Anteris Technologies
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is recognized for its unwavering commitment to innovate in the field of structural heart disease. Founded in Australia with a robust presence in Minneapolis, USA, the company is committed to advancing medical technology that restores healthy heart function. The DurAVR® Transcatheter Heart Valve (THV) stands as a premier product designed in collaboration with key experts in interventional cardiology and cardiac surgery, intended for treating aortic stenosis, a potentially life-threatening condition. This valve's design mirrors the function of a healthy aortic valve, promoting optimized aortic blood flow and enhancing patient outcomes significantly.
Constructed from Anteris’ proprietary ADAPT® tissue, recognized for its anti-calcification properties, the DurAVR® THV aims to provide a reliable solution for patients worldwide, further validating Anteris’ promise to deliver high-quality medical solutions.
Frequently Asked Questions
What are the key findings of the DurAVR® THV's one-year results?
The one-year results demonstrate a favorable hemodynamic profile, high effective orifice areas, no valve-related mortality, and minimal prosthesis-patient mismatch.
How does the DurAVR® THV perform for patients with small aortic annuli?
The DurAVR® THV shows excellent outcomes for small annuli patients by maintaining low pressure gradients and minimizing complications related to paravalvular leaks.
What is the significance of the PARADIGM Trial?
The PARADIGM Trial is a pivotal randomized controlled trial aimed at comparing the DurAVR® THV with existing transcatheter aortic valve replacements, focusing on long-term safety and efficacy.
How does Anteris Technologies contribute to heart health advancements?
Anteris is committed to developing cutting-edge medical devices that enhance heart function and improve outcomes for patients with structural heart disease.
What makes the DurAVR® THV unique?
The DurAVR® THV is distinct for its biomimetic design, mimicking a healthy aortic valve which optimizes blood flow, and its use of ADAPT® tissue that has been effective for over a decade.
